Role of oral ketamine in treatment resistant depression

Efficacy and safety of repeated oral ketamine in treatment resistant depression - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/081238

Enrollment

Registered

2025-02-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F339- Major depressive disorder, recurrent, unspecified

Interventions

Intervention1: Repeated oral ketamine in treatment resistant depression: 50 patients of depression fulfilling inclusion and exclusion criteria will be recruited from Psychiatry OPD after making the di

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects who will meet the ICD 10 criteria for Major Depressive Disorder. 2. Subjects who score more than 12 (moderate to severe) on Hamilton Depression Rating Scale. 3. Subjects who got no adequate response with 2 antidepressants. 4. Subjects who will give informed consent for this study.

Exclusion criteria

Exclusion criteria: 1.Subjects who will not give informed consent for study. 2. Subjects having any contraindication to administration of ketamine. 3. Subjects having any other psychiatric or physical comorbidities.

Design outcomes

Primary

Measure	Time frame
A change of 50% in HAM-D score will be considered as response.Timepoint: 2 years	—

Secondary

Measure	Time frame
1.To see comparative effectiveness in both groups. 2. To see the tolerability and adverse effects in both groups. 3. To see the development of ketamine dependence in both groups. Timepoint: 2 years	—

Countries

India

Contacts

Public ContactDr Mohammed Reyazuddin

Jawaharlal Nehru Medical College And Hospital

reyaz39@gmail.com9997258800

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026